Ophthalmology Drug Development and Acquisitions North America · 1d ago

Johnson & Johnson Acquires Ollin Biosciences for $2.2 Billion to Advance Phase 3 Retinal Drug in the US

Johnson & Johnson agrees to acquire Ollin Biosciences for $2.2 billion, adding Phase 3 retinal drug candidate OLN324 to its ophthalmology pipeline.

RD

Research Desk

· 2 min read

Johnson & Johnson Acquires Ollin Biosciences for $2.2 Billion to Advance Phase 3 Retinal Drug in the US

Johnson & Johnson announced that it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.

The deal is valued at USD 2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments of up to approximately USD 1.125 billion. The transaction is expected to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions.

A Bispecific Antibody Aimed at Two Retinal Pathways

At the center of the transaction is OLN324, an investigational bispecific antibody currently in Phase 3 development for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema.

According to Johnson & Johnson's announcement, those conditions affect well over 40 million people worldwide and are leading causes of vision loss. The molecule is designed to target two key pathways in retinal diseases: vascular endothelial growth factor, known as VEGF, and angiopoietin-2, known as Ang2.

Johnson & Johnson describes OLN324 as a next-generation antibody with high Ang2 potency and a small protein format, referred to as a minibody, that could enable improved control of retinal fluid.

Kip Connor, Vice President and Ophthalmology Disease Area Stronghold Leader at Johnson & Johnson, said the compound selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control.

He stated that the data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients.

Blackstone Steps In to Fund Phase 3 Development

Alongside the acquisition, Johnson & Johnson will enter into a separate development funding agreement with Blackstone Life Sciences to support the Phase 3 clinical advancement of OLN324, contingent upon the acquisition's close.

Under that arrangement, Blackstone will pay a total of USD 750 million to Johnson & Johnson over multiple years to fully fund the Phase 3 development of OLN324. In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments as well as single-digit royalties.

The accounting treatment will be communicated on or before the close of the transaction.

Strategic Rationale for Johnson & Johnson

The acquisition would add OLN324 to Johnson & Johnson's pipeline. The company stated that its combination of scientific, development, and commercial capabilities positions it to advance OLN324 and build on Ollin's promising science.

Johnson & Johnson framed the proposed acquisition as strengthening its leadership in ophthalmology and its commitment to preserve, restore, and enhance vision for millions of people worldwide.

The deal is also described as accelerating the company's ambition to preserve, restore, and enhance vision and as building on Johnson & Johnson's long-standing presence as an innovator in vision.

Tracked in the database

Ophthalmology Drug Development and Acquisitions · North America

Category

Ophthalmology Drug Development and Acquisitions

Region

North America

Industry

Chemical

Published

17 November 2026

Length

2 min read

Tagged

Johnson & JohnsonOllin Biosciences acquisitionOLN324 bispecific antibodyBlackstone Life Sciences funding

Live from the tracker

The projects behind these stories

Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.

LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning